louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02196532: Retinal Nerve Fiber Layer Thickness Changes in Migraine: A Meta-Analysis of Case-control Studies
Official title: Retinal Nerve Fiber Layer Thickness Changes in Migraine: A Meta-Analysis of Case-control Studies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Migraine
Keywords: retinal nerve fiber layer thickness
optical coherence tomography
migraine
Lead sponsor: Wenzhou Medical University
Sponsor class: OTHER
Collaborators: name: Fudan University
First posted: 2014-07-22
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Migraine patients and healthy subjects were included and underwent OCT examinations

Brief summary: Optical coherence tomography (OCT) is a non-invasive retinal imaging technology that can provide high-resolution cross-sectional images of the peripapillary retinal nerve fiber layer (RNFL) and measure its thickness. A reduction of the RNFL thickness has been detected in several neurodegenerative diseases, such as multiple sclerosis, CADASIL and Alzheimer's disease. Different studies have reported RNFL changes also in migraine, is a common hereditary chronic neurovascular disorder, characterized by dysfunction of the autonomic nervous system. The pathophysiology of migraine has not been fully clarified, but there is increasing evidence that episodes of migraine with aura are initiated by a focal reduction in cerebral blood flow, which occurs most commonly in the posterior region of one hemisphere. Although vasoconstriction of cerebral and retinal blood vessels is a transient phenomenon, the chronic nature of the migraine might cause permanent structural abnormalities of the brain and also of the retina, which may correlate with RNFL thinning. Previous studies on this subject, however, reported contradicting results. Some investigations reported reductions of the RNFL thickness while others did not. In the present study, in order to determine whether RNFL thickness is reduced in migraine patients, the investigators performed a meta-analysis and systematically evaluated RNFL thickness measurements with OCT in a series of migraine patients and in the healthy control groups.


Eligibility criteria: Inclusion Criteria:

1. case-control studies;
2. patients with Migraine were compared with healthy controls;
3. all subjects underwent RNFL thickness measurement by OCT;
4. studies should provide the data of peripapillary RNFL thickness;
5. sample size ≥10 in each group.

Exclusion Criteria:

1. authors did not make RNFL measurements;
2. study without healthy control group;
3. the outcome values can not be used for meta-analysis;
4. duplicated articles.

Primary outcomes:
measure: Retinal Nerve Fiber Layer Thickness
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Zhongshan hospital, Fudan University
state: Shanghai
Study officials:
affiliation: Fudan University
name: Yifan Feng, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06764732: Socket Seal Surgery
Official title: Laser Assisted Socket Seal Surgery Using Bioactive Glass for Dental Implant Site Development
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Socket Sealing
Keywords: bio active glass
socket preservation
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2025-01-08
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: laser photo biomodulation (PBM) as a supplement to socket seal surgery

Detailed description: the role of PBM therapy as an adjunct for bioactive glass graft in SSS approaches

Eligibility criteria: Inclusion Criteria:

* Presence of at least a periodontal-affected and non-restorable tooth in posterior region (Class II sockets).
* At least 10% plaque control scoring was accepted
* A moderate to thick gingival phenotype

Exclusion Criteria:

* systemic diseases or conditions that may compromise healing or bone metabolism,
* having a history of radiotherapy, chemotherapy or bisphosphonate therapy, previous use of antibiotics in the last 3

Primary outcomes:
measure: alveolar ridge dimensional changes in height and width measures
timeFrame: at base line and after 9 months
Secondary outcomes:
measure: bone biopsy
timeFrame: after 9 months
Other outcomes:
Locations:
city: Dakahlia
country: Egypt
facility: , Faculty of Oral and Dental Medicine, Delta University for Science and Technology (DU), Dakahlia, Egypt
Study officials:
References:
Clinical trial NCT03542032: Comparison of I-Gel Laryngeal Mask Airway Placement Methods in Elective Surgery
Official title: Comparison of I -Gel Mask Airway Placement Methods in Elective Surgery: Jaw Thrust Maneuver vs Conventional Technique
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Effective I -Gel Mask Airway Placement Technique
Keywords: i-gel
jaw-thrust
Lead sponsor: Ankara Diskapi Training and Research Hospital
Sponsor class: OTHER
First posted: 2018-05-31
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To compare the jaw thrust maneuver with the conventional technical methods to place the I-Gel laryngeal mask

Detailed description: Patients who underwent elective surgery under general anesthesia and who were between the ages of 18 and 75 and who had ASA score I-II-III would be included in the study. Patients' mallampati scores, thyromental distances, mouth openings will be recorded.

Patients will be divided into two groups according to supraglottic airway insertion method.

Both groups will record the insertion time of i-gel, number of trials, operative time, placement complications.

Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.

Patients' postoperative sore throat will be questioned and recorded.

Eligibility criteria: Inclusion Criteria:

1. Patients between the ages of 18 and 75 years
2. American Society of Anesthesiologists I, II or III

Exclusion Criteria:

1. Those with anatomical disorders related to the upper airway
2. lung disease
3. gastric regurgitation
4. Those who have had lung infection in the last 3 weeks
5. Supraglottic airway vehicle not settled
6. Those who are hired for any reason
7. EtCO2\> 45

American Society of Anesthesiologists 4 or 5

-

Primary outcomes:
measure: insertion time
timeFrame: 2 minutes
measure: successful insertion number
timeFrame: 2 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Diskapi Yildirim Beyazit Training Research Hospital
Study officials:
References:
Clinical trial NCT00554437: Kenosha County Falls Prevention Study
Official title: Kenosha County Falls Prevention Study: An Intermediate-intensity, Community-based, Multifactorial Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Accidental Falls
Keywords: Accidental Falls
RCT
Age 65 and older
noninstitualized populations
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
Collaborators: name: Kenosha County Aging and Disability Resource Center
name: Wisconsin Department of Health and Family Services
First posted: 2007-11-06
Enrollment: 349
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Intensive falls prevention programs have been shown to be effective in reducing falls; however, a number of practical programs, based in community setting have not been successful at reducing rate of falls. The purpose of this study was to test, in a randomized, controlled trial, the efficacy of this intermediate-intensity, individual, multifactorial model to reduce falls. It was hypothesized that more contacts would lead to greater adherence and efficacy in reducing falls.


Eligibility criteria: Inclusion Criteria:

* aged 65 and older
* a history of two falls in the previous year or one fall in the previous two years with injury or gait and balance problems
* independently living in Kenosha County

Exclusion Criteria:

* unable to give informed consent with no related caregiver in the home
* enrolled in hospice
* living in an assisted-living facility
* expecting to move away permanently from the area

Primary outcomes:
measure: rate of falls
timeFrame: one year
Secondary outcomes:
measure: all-cause hospitalizations
timeFrame: one year
measure: nursing home utilizations: number of days and number of admissions
timeFrame: one year
measure: change in ADL function from baseline to one year
timeFrame: one year
Other outcomes:
Locations:
Study officials:
affiliation: University of Wisconsin, Madison
name: Jane E Mahoney, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mahoney JE, Shea TA, Przybelski R, Jaros L, Gangnon R, Cech S, Schwalbe A. Kenosha County falls prevention study: a randomized, controlled trial of an intermediate-intensity, community-based multifactorial falls intervention. J Am Geriatr Soc. 2007 Apr;55(4):489-98. doi: 10.1111/j.1532-5415.2007.01144.x.
Clinical trial NCT03164837: 68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients
Official title: Safety and Diagnostic Performance of 68Gallium-labeled NOTA-RM26 PET/CT in Prostate Cancer Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Prostate Cancer
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
Collaborators: name: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
First posted: 2017-05-24
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-RM26 in prostate cancer patients. A single dose of 111-148 Mega-Becquerel (MBq) 68Ga-NOTA-RM26 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

Detailed description: The gastrin-releasing peptide receptor (GRPR), also known as bombesin receptor subtype II (BB2), is a member of the G protein-coupled receptor family of bombesin receptors. GRPR is over-expressed in various types of human tumors including prostate cancer. RM26, a GRPR antagonist with high affinity, was discovered by peptide backbone modification of bombesin analogues.To target gastrin-releasing peptide receptor in neoplastic cells of human prostate cancer, peptide NOTA-RM26 was synthesized with a PEG3 linker between NOTA and RM26, and then labeled with 68Ga. An open-label whole-body PET/ CT study was designed to investigate the safety and dosimetry of 68Ga-NOTA-RM26 and to assess its clinical diagnostic value in patients with prostate cancer.

Eligibility criteria: Inclusion Criteria:

* Patients with diagnosis of primary prostate cancer having a prostate neoplasm identified by ultrasound or MRI, being diagnosed by needle biopsy as having prostate cancer, having undergone whole-body bone scanning, and being able to provide basic information and sign the written informed consent form.

Exclusion Criteria:

* The exclusion criteria included claustrophobia, kidney or liver failure, and inability to fulfill the study.

Primary outcomes:
measure: Standardized uptake value of 68Ga-NOTA-RM26 in prostate cancer
timeFrame: 1 year
Secondary outcomes:
measure: Adverse events collection
timeFrame: 1 week
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
name: Zhaohui Zhu, M.D.,PhD.
role: STUDY_CHAIR
References:
Clinical trial NCT03012737: Palliation of Dyspnea With Mouth Piece Ventilation
Official title: Palliation of Dyspnea With Mouth Piece Ventilation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Dyspnea
Lead sponsor: Tampere University Hospital
Sponsor class: OTHER
First posted: 2017-01-06
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: An uncontrolled feasibility study on using mouth piece ventilation in palliation of dyspnea in subjects with incurable advanced disease. Subjects are recruited from a local Hospice and from oncology ward. The main outcomes are the compliance of the subjects with the treatment and alleviation of dyspnea during the treatment period.


Eligibility criteria: Inclusion Criteria:

* at least moderate dyspnea (NRS = Numeric Rating Scale ≥ 4)
* incurable advanced disease
* able to understand the study and to give informed consent
* would not gain from intensive care or resuscitation according to the treating physician

Exclusion Criteria:

* unable to participate and use MPV due to e.g. delirium or lack of co-operation
* the cause of the dyspnea can be succesfully treated
* unable to give informed consent

Primary outcomes:
measure: Change in dyspnea after initial use of MPV
timeFrame: 5 - 60 min
Secondary outcomes:
measure: Change in dyspnea after 24 hours of using MPV
timeFrame: 24 hours
measure: Proportion of subjects having side-effects or not being compliant with MPV
timeFrame: 24 hours
measure: Proportion of subjects gaining from MPV
timeFrame: 24 hours
measure: Proportion of subjects willing to continue on MPV after the intervention
timeFrame: 24 hours
Other outcomes:
Locations:
city: Tampere
country: Finland
facility: Dpt of oncology, Tampere University Hospital
city: Tampere
country: Finland
facility: Pirkanmaa Hospice
Study officials:
affiliation: Tampere University Hospital
name: Lauri Lehtimäki, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lehto JT, Leivo-Korpela S, Korhonen T, Rantala HA, Raunio H, Lyly-Yrjanainen T, Lehtimaki L. Mouthpiece ventilation in the management of dyspnea: A single-arm pilot study. Palliat Med. 2020 Oct;34(9):1274-1278. doi: 10.1177/0269216320935003. Epub 2020 Jun 24.
Clinical trial NCT03927937: Tooth Autotransplantation and Bone Dimension Changes
Official title: Tooth Autotransplantation and Bone Dimension Changes. Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bone Loss, Alveolar
Tooth Loss
Bone Atrophy, Alveolar
Lead sponsor: Universidad de Murcia
Sponsor class: OTHER
First posted: 2019-04-25
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Tooth autotransplantation is a treatment option to replace tooth with imposible prognosis. In several cases the receipt site has a reduced bone dimension. This situation may be imposible the treatment with dental implants without bone reconstruction. Autotransplantation seem to improve the anatomic characteristic of the receipt site without any reconstruction approach.

The aim of this study is to evaluate the bone dimension changes followed autotransplantation treatment.


Eligibility criteria: Inclusion Criteria:

* Tooth with imposible prognosis
* Plaque index score less than 30%
* No relevant systemic disease
* Smokers (Less than 20 cigars/day)

Exclusion Criteria:

* Pregnancy-Lactation
* Relevant systemic disease

Primary outcomes:
measure: Change in alveolar bone 12 months after tooth autotransplantation
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Murcia
country: Spain
facility: Universidad de Murcia
Study officials:
References:
Clinical trial NCT01123837: A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting
Official title: A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Nausea and Vomiting
Lead sponsor: Loma Linda University
Sponsor class: OTHER
First posted: 2010-05-14
Enrollment: 202
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: "The purpose of this investigator-initiated study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood surgery level. The reason for this study is that IV dextrose has been shown to decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction."


Eligibility criteria: Inclusion Criteria:

1. ASA I or II
2. female urologic, gynecologic and breast surgery patients undergoing scheduled same day procedures at LLUMC Heart and Surgical Hospital

Exclusion Criteria:

1. age \<18 or \>65;
2. severe hypertension,diabetes mellitus, significant hepatic or renal disease
3. excessive blood loss
4. sustained (\>10 min)\>20% from baseline drop in BP after treatment
5. inability to follow protocol
6. refusal to sign consent

Primary outcomes:
measure: A Closer Look at the Effect of Glucose on Postoperative Nausea and Vomiting
timeFrame: approximately 24 hours
Secondary outcomes:
measure: A Closer Look at the Effect of Dextrose on Post-operative nausea and vomiting
timeFrame: approximately 24 hours
Other outcomes:
Locations:
city: Loma Linda
country: United States
facility: Loma Linda University Medical Center Heart and Surgical Hospital
state: California
Study officials:
affiliation: Loma Linda University Medical Center
name: Richard L Applegate, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02224937: MELATOX: Evaluation of Percutaneous Dissolvement of Melatonin When Used as Sunscreen; a Randomized, Placebo Controlled, Double-blind Crossover Study on Healthy Volunteers.
Official title: MELATOX: Evaluation of Percutaneous Dissolvement of Melatonin When Used as Sunscreen; a Randomized, Placebo Controlled, Double-blind Crossover Study on Healthy Volunteers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solar Skin Damage
Keywords: Melatonin
Cognitive parameters
pharmacodynamic
pharmacokinetics
Lead sponsor: Zealand University Hospital
Sponsor class: OTHER
First posted: 2014-08-25
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the percutaneous transportation and pharmacokinetics of melatonincream 12,5% when used on 80% of the body area. A test battery consisting of blood, saliva, urine samples at 1,2,3,4,5,6,7,8,12,24 and 36 hours after cream application. Cognitive parameters are investigated using KSS, FTT and CRT tests at above mentioned time points.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers of both sexes
* Age 18-65 years
* No shiftwork
* No intake of caffeine or alcohol one day before investigation, and under the experiment.
* Pittsburgh sleep quality index \<5
* Height 165-190 cm
* Weight 53-85 kg

Exclusion Criteria:

* Pregnancy
* Active skin-disease
* Use of hypnotic or sedative drugs.
* Known sleeping disorder
* Known allergy to contents of the cream.

Primary outcomes:
measure: Changes in Karolinska Sleepiness Scale after application of melatonincream 12,5% on 80% of the body-surface area.
timeFrame: 1,2,3,4,5,6,7,8,12,24 and 36 hours post exposure.
Secondary outcomes:
measure: Changes in continuous reaction time over a time period of 36 hours after application of melatonin cream 12,5% on 80% of the body surface area.
timeFrame: 1,2,3,4,5,6,7,8,12,24 and 36 hours post exposure.
measure: Changes in finger tapping test over a time period of 36 hours after application of melatonin cream 12,5% on 80% of the body surface area.
timeFrame: 1,2,3,4,5,6,7,8,12,24 and 36 hours post exposure.
measure: Changes in serum melatonin concentration
timeFrame: 1,2,3,4,5,6,7,8,12,24 and 36 hours post exposure.
measure: Changes in saliva melatonin concentration.
timeFrame: 1,2,3,4,5,6,7,8,12,24 and 36 hours post exposure
measure: Changes in urine melatonin concentration
timeFrame: 0-4,4-8,8-12,12-24 and 24-36.
Other outcomes:
measure: Measurement changes in bloodpressure and puls.
timeFrame: 1,2,3,4,5,6,7,8,12,24 and 36 hours post exposure
measure: Holter monitoring
timeFrame: 1-36 hours
measure: Measurement of changes in body-temperature
timeFrame: 1,12,24 and 36 hours post exposure
Locations:
city: Herlev
country: Denmark
facility: Herlev Sygehus
Study officials:
affiliation: Køge Sygehus
name: Cecilie Ms Scheuer, ph.d.student
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03391037: Internal Jugular Vein Distensibility in Assessment of Fluid Responsiveness in Donors of Living Donor Liver Transplantation
Official title: Internal Jugular Vein Distensibility in Assessment of Fluid Responsiveness in Donors of Living Donor Liver Transplantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Monitoring During Anesthesia
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2018-01-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Prospective blinded observational study

Brief summary: Egypt has a very high prevalence of HCV and a high morbidity and mortality from chronic liver disease, cirrhosis, and hepatocellular carcinoma. Approximately 20% of Egyptian blood donors are anti-HCV positive. Egypt has higher rates of HCV than neighboring countries as well as other countries in the world with comparable socioeconomic conditions and hygienic standards for invasive medical, dental, or paramedical procedures.

Donor safety is on the top of our priorities as a team and it is widely recognized intraopertively during hepatectomy, there are several potential risks during the Perioperative period .

Detailed description: to a conclusion that intraoperative fluid management aids to the reduction of the intraoperative bleeding during the procedure, adequate and guided fluid management is considered one of the important strategies to reduce the blood loss besides of the other anesthetic techniques like hemodilution, normovolemia, cell salvage usage , high Stroke volume variation (SVV) method ,and low CVP technique , the last method is considered the most applicable, simpler, and cost effective technique which could be easier to be performed.

Eligibility criteria: Inclusion Criteria:

* age of 20 years . candidate for donor right lobe hepatectomy for LDLT . volume assessment diagnosed as hypovolemia intraopertively by the anesthesiologist.

Exclusion Criteria:

* inability to scan IJV secondary to surgical dressing, hematoma formation after trial or placement of CVP catheter on left side.

inability for proper positioning.

Primary outcomes:
measure: correlation between CVP and IJV distensibility
timeFrame: 10 min
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: